- 抑制劑
- 化合物庫
- 抗體
- 生物試劑
- 新產(chǎn)品
- 聯(lián)系我們
別名: GOE 6983, G? 6983
Go 6983 (GOE 6983, G? 6983)是一種pan-PKC抑制劑,作用于PKCα, PKCβ, PKCγ和PKCδ,IC50分別為7 nM, 7 nM, 6 nM和10 nM,對PKCζ作用稍弱,抑制PKCμ活性。
Go 6983 Chemical Structure
CAS: 133053-19-7
細胞系 | 實驗類型 | 給藥濃度 | 孵育時間 | 活性描述 | 文獻信息 |
---|---|---|---|---|---|
KM20 | Function assay | 2 μM | 8 h | attenuated PMA-induced FLIP mRNA expression | 16052516 |
HT29 | Function assay | 2 μM | 8 h | attenuated PMA-induced FLIP mRNA expression | 16052516 |
HCT116 | Function assay | 2 μM | 8 h | attenuated PMA-induced FLIP mRNA expression | 16052516 |
PC-3 | Function assay | 1 μM | 2 h | G?6983 abrogates the TPA-induced RGFR transactivation response | 15897236 |
KM12C | Function assay | 2 μM | 8 h | attenuated PMA-induced FLIP mRNA expression | 16052516 |
Caco-2 | Function assay | 2 μM | 8 h | completely attenuated PMA-induced FLIP mRNA expression | 16052516 |
A549 | Function assay | 10 μM | 1 h | markedly inhibited ATPγS-stimulated NADPH oxidase activity and H2O2 and/or ROS generation | 23326583 |
HeLa | Function assay | 2 μM | 48 h | suppressed the effect of PMA on apicularen A-induced cytotoxicity | 24447339 |
PC12 | Function assay | 0.5 μM | GO6983 blocked the effect of PMA on the activation of Akt and MAPK induced by IGF-1 | 10788447 | |
A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 29435139 | ||
NB-EBc1 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 29435139 | ||
SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 29435139 | ||
LAN-5 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 29435139 | ||
NB1643 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells | 29435139 | ||
SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells | 29435139 | ||
LAN-5 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells | 29435139 | ||
DAOY | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells | 29435139 | ||
BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells | 29435139 | ||
TC32 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells | 29435139 | ||
Rh41 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells | 29435139 | ||
Rh30 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells | 29435139 | ||
OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells | 29435139 | ||
SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells | 29435139 | ||
HEK293 | Function assay | Inhibition of Cav1.2 calcium current measured using whole cell patch clamp in human HEK293 cells transfected with rabbit L-type calcium channel subunits, IC50 = 20 μM. | ChEMBL | ||
點擊查看更多細胞系數(shù)據(jù) |
產(chǎn)品描述 | Go 6983 (GOE 6983, G? 6983)是一種pan-PKC抑制劑,作用于PKCα, PKCβ, PKCγ和PKCδ,IC50分別為7 nM, 7 nM, 6 nM和10 nM,對PKCζ作用稍弱,抑制PKCμ活性。 | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
靶點 |
|
體外研究(In Vitro) | ||||
體外研究活性 | Gö 6983(300 μM)作用于轉(zhuǎn)染PKCμ的NIH3T3細胞,抑制PKCμ自磷酸化,降低20%。[1] 心臟再灌注PMNs和Gö 6983 (100 nM),左心室發(fā)展壓(LVDP)和LVDP率分別恢復(fù)到基準值的89%和74%,顯著高于PMNs單獨處理。與心臟缺血再灌注(I/R)+ PMN 相比,Gö 6983 (100 nM)顯著降低PMNs黏附到內(nèi)皮細胞和浸潤到心肌,且顯著抑制超氧化物從PMNs中釋放,抑制達90%。在PMNs存在時,Gö 6983降低I/R后心肌收縮功能障礙,這可能與降低超氧化物的產(chǎn)生部分相關(guān)。[2] Gö 6983顯著抑制抗原誘導(dǎo)的超氧化物從以前對樹花粉過敏的患者白細胞中釋放。Gö 6983作用于人類血管組織,抑制細胞內(nèi)的Ca(2+)累積,說明其血管舒張?zhí)匦詸C制。[3] Go-6983(1 μM)與Ro-31-8425(390 nM)聯(lián)用作用于PGSMCs,輕微抑制Angiotensin II誘導(dǎo)的PLD2活性。[4] Gö 6983 是亞型特異性的PKC抑制劑,靶向作用于ATP 結(jié)合位點。Gö 6983抑制ΔPfPKB活性,IC50為1 μM。Gö 6983(5 μM)處理過的細胞中,與對照培養(yǎng)物相比,下一細胞周期環(huán)數(shù)顯著減少。Gö 6983 (5 μM) 處理P. falciparum培養(yǎng)物,使新環(huán)形成減少近60%。[5] |
|||
---|---|---|---|---|
實驗圖片 | 檢測方法 | 檢測指標 | 實驗圖片 | PMID |
Western blot | PKCη / PKCα / PKCδ / PKCε |
![]() |
22892130 |
體內(nèi)研究(In Vivo) | ||
體內(nèi)研究活性 | 在小鼠肺B16BL6腫瘤模型中,Go6983 (22.0 μg/mouse, i.v.)強烈抑制51.2 %的腫瘤轉(zhuǎn)移。[6] |
---|
分子量 | 442.51 | 分子式 | C26H26N4O3 |
CAS號 | 133053-19-7 | SDF | Download Go 6983 SDF |
Smiles | CN(C)CCCN1C=C(C2=C1C=CC(=C2)OC)C3=C(C(=O)NC3=O)C4=CNC5=CC=CC=C54 | ||
儲存條件(自收到貨起) | |||
體外溶解度 |
DMSO : 89 mg/mL ( (201.12 mM) ;DMSO吸濕會降低化合物溶解度,請使用新開封DMSO) Water : Insoluble Ethanol : Insoluble |
摩爾濃度計算器 |
體內(nèi)溶解度 現(xiàn)配現(xiàn)用,請按從左到右的順序依次添加,澄清后再加入下一溶劑 |
動物體內(nèi)配方計算器 |
動物體內(nèi)配方計算器(澄清溶液)
第一步:請輸入基本實驗信息(考慮到實驗過程中的損耗,建議多配一只動物的藥量)
第二步:請輸入動物體內(nèi)配方組成(配方適用于不溶于水的藥物;不同批次藥物配方比例不同,請聯(lián)系Selleck為您提供正確的澄清溶液配方)
計算結(jié)果:
工作液濃度: mg/ml;
DMSO母液配制方法: mg 藥物溶于μL DMSO溶液(母液濃度mg/mL,注:如該濃度超過該批次藥物DMSO溶解度,請先聯(lián)系Selleck);
體內(nèi)配方配制方法:取μL DMSO母液,加入μL PEG300,混勻澄清后加入μL Tween 80,混勻澄清后加入μL ddH2O,混勻澄清。
體內(nèi)配方配制方法:取μL DMSO母液,加入μL Corn oil,混勻澄清。
注意:1. 首先保證母液是澄清的;
2.一定要按照順序依次將溶劑加入,進行下一步操作之前必須保證上一步操作得到的是澄清的溶液,可采用渦旋、超聲或水浴加熱等物理方法助溶。
在訂購、運輸、儲存和使用我們的產(chǎn)品的任何階段,您遇到的任何問題,均可以通過撥打我們的熱線電話400-668-6834,或者技術(shù)支持郵箱tech@selleck.cn,直接聯(lián)系到我們。我們會在24小時內(nèi)盡快聯(lián)系您。
如果有其他問題,請給我們留言。
* 必填項